How to Value a Durable Medical Equipment (DME) Business in 2026

I've advised on dozens of DME transactions over the past decade, and the one thing that consistently surprises sellers is how much the payer mix on their books affects the price. Two DME companies with identical revenue can trade at wildly different multiples depending on whether their revenue comes from Medicare fee schedule items or commercial insurance contracts. Let me break down exactly how DME valuations work and what you can do to position your business for the strongest exit.

DME Valuation Multiples: What the Data Shows

Our database includes 174 DME transactions, which gives us a statistically meaningful picture of this market. The headline numbers: median EV/EBITDA of 8.59x and median EV/Revenue of 0.88x. But those medians hide enormous variation based on size and business composition.

For businesses under $5M in enterprise value — the bread and butter of the independent DME supplier market — expect multiples around 5.29x EBITDA and 0.6x revenue. These are typically single-location operators with a limited product mix and heavy Medicare dependence. Move into the $5-25M range and multiples climb to 5.4x EBITDA and 0.85x revenue, reflecting greater scale and typically a more diversified payer base.

The overall market trend is stable. DME isn't a hypergrowth sector, but the aging population provides a long secular tailwind. The real opportunity is in how you position your business within the sub-segments of this market.

Complex Rehab vs. Commodity Supplies: Two Different Businesses

This is the most important distinction in DME valuation, and I see sellers misunderstand it constantly. The DME industry has two fundamentally different business models operating under the same umbrella.

Complex rehab technology (CRT) — power wheelchairs, custom seating systems, ventilators, complex orthotics — carries higher margins (often 35-50% gross), higher barriers to entry, and stronger customer relationships. These products require clinical expertise to fit and deliver, creating a natural moat. CRT companies with strong rehab technician teams routinely trade at the upper end of the multiple range, and PE buyers actively seek them because the clinical workflow creates defensibility.

Commodity supplies— CPAP machines and masks, standard walkers, hospital beds, basic oxygen equipment — are volume-driven businesses with thinner margins (20-30% gross) and intense price competition. These businesses are more vulnerable to competitive bidding, mail-order competitors, and online retailers encroaching on the space. They trade at lower multiples unless they've built real scale or locked in recurring resupply programs.

In my experience, a CRT-focused DME company with $2M EBITDA might command 6-7x, while a commodity-focused supplier at the same EBITDA level might struggle to break 4.5x. The clinical expertise and patient relationships are that valuable.

Payer Mix: The Single Biggest Value Driver

If there's one metric that drives DME valuation more than any other, it's payer mix. I've seen this swing deal values by 30% or more.

Medicare/Medicaid revenue is a double-edged sword. It provides volume and predictability, but it comes with reimbursement risk, audit exposure, and the ever-present threat of fee schedule cuts. Businesses heavily dependent on government payers (70%+ of revenue) get discounted by buyers who have lived through CMS rate adjustments and know another one is always coming.

Commercial insurance revenue typically reimburses at 20-40% above Medicare rates, and contracts are more stable year to year. A DME business with 40-50% commercial payer mix signals stronger margins and less regulatory risk.

Workers' compensation and VA contracts are premium revenue sources. They reimburse well, pay reliably, and often involve complex equipment that commands higher margins. Buyers love seeing 15-20% of revenue from these sources.

The ideal profile I've seen fetch top multiples: roughly 40% Medicare, 35% commercial, 15% workers' comp/VA, and 10% cash pay or other. That diversification protects against any single payer action devastating your business.

Accreditation and Compliance: Non-Negotiable for Buyers

Every buyer I work with in DME asks about accreditation status before they look at a single financial statement. Current accreditation from ACHC (Accreditation Commission for Health Care), BOC (Board of Certification/Accreditation), or The Joint Commission is table stakes. Without it, you cannot bill Medicare, and your business is effectively unsalable to any institutional buyer.

But accreditation status alone isn't enough. Buyers conduct deep compliance due diligence because CMS audit risk is real and material. The items that kill deals or crater valuations:

• Open audit findings or ADR (Additional Documentation Request) patterns: If you're getting ADRs on a high percentage of claims, buyers see a business with documentation problems that could result in recoupment demands.
• Supplier standards deficiencies: Unresolved accreditation findings signal operational sloppiness that carries regulatory risk.
• Competitive Bidding Program exposure: If a significant portion of your revenue comes from items in CMS competitive bidding areas, buyers know those rates can be reset every three years — and they've seen rates cut 30-40% in previous rounds.
• Prior authorization compliance: With CMS expanding prior authorization requirements, a business that lacks systems to manage PA workflows faces revenue disruption risk.

I tell every DME seller: get your compliance house in order 12-18 months before going to market. A clean compliance history is worth real money at the closing table.

Recurring Supply Revenue: The Hidden Premium

One of the most overlooked value drivers in DME is the recurring resupply component. CPAP masks and supplies, diabetic testing supplies, urological supplies, ostomy products — these are items patients reorder every 30-90 days. A well-run resupply program generates recurring revenue with minimal incremental cost per order.

I've seen DME businesses where resupply revenue accounts for 40-60% of total revenue, and those businesses consistently trade at premium multiples. The math is compelling: a patient on CPAP therapy who reorders supplies quarterly generates $800-$1,200 per year in recurring revenue with 50%+ gross margins. Build a base of 5,000 active resupply patients and you've got $4-6M in predictable annual revenue.

Buyers price resupply revenue at a premium because it's sticky, predictable, and scalable. If you're running a DME business and not aggressively building your resupply program, you're leaving significant value on the table.

Referral Relationships: Critical but Fragile

DME businesses live and die by their referral relationships with hospitals, physicians, sleep labs, and discharge planners. A strong referral network is worth a great deal — but buyers know it's also fragile. The key question every acquirer asks: will the referral sources keep sending patients after the ownership changes?

Businesses where referral relationships are institutionalized (contracts with hospital systems, preferred vendor agreements, embedded staff in clinical settings) are worth far more than businesses where referrals depend on the owner's personal relationships. I worked on a deal where the seller had personal friendships with 15 pulmonologists who drove 70% of referrals. The buyer discounted the deal by 20% to account for referral attrition risk.

If you're preparing to sell, formalize your referral relationships. Get preferred vendor agreements in writing. Assign account managers to key referral sources so the relationship transfers with the business, not with you.

What Buyers Are Looking For in 2026

The DME M&A market is active, with both strategic acquirers and PE-backed platforms looking for acquisitions. Here's what I see buyers prioritizing:

• Diversified product mix: Businesses that span CRT, respiratory, and resupply are more attractive than single-category specialists.
• Technology adoption: Modern inventory management, electronic ordering, automated resupply outreach, and telehealth integration signal an operator who invests in efficiency.
• Geographic footprint: Multi-location DME businesses that serve a defined geography with delivery infrastructure are more defensible than single-location operators.
• Clean documentation practices: In an industry where CMS can recoup years of payments based on documentation deficiencies, buyers obsess over documentation quality.

How to Maximize Your DME Business Value

Based on the deals I've worked, here are the highest-impact moves for DME sellers preparing to exit:

Build the resupply engine. Invest in automated outreach, patient compliance tracking, and a dedicated resupply team. Every resupply patient you add is annuity revenue that buyers will pay a premium for.

Diversify your payer mix.If you're over 70% Medicare, aggressively pursue commercial contracts. Add workers' comp and VA if your product mix supports it. Even shifting 10% of revenue from government to commercial payers measurably improves your multiple.

Invest in compliance infrastructure.Hire a compliance officer or engage a compliance consultant. Implement internal audit programs. Maintain spotless accreditation records. Buyers will pay more for a business they trust won't generate regulatory surprises.

Formalize referral relationships. Move from handshake arrangements to documented agreements. Assign account managers. Track referral volumes by source so you can demonstrate stability to buyers.

The Bottom Line

DME is a sector where the spread between well-positioned and poorly-positioned businesses is enormous. A commodity supply house with heavy Medicare dependence and owner-dependent referrals might trade at 3.5-4x EBITDA. A diversified DME platform with CRT capabilities, strong resupply revenue, commercial payer mix, and clean compliance might fetch 7-8x. The fundamentals are the same — it's how you structure and operate the business that determines where you fall on that spectrum. If you're considering an exit in the next 2-3 years, start working on these levers now. The preparation period is where the real value creation happens.